Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Growth Hormone Secretion

Hulk Stack

Hulk blend; IGF-1 LR3 + CJC-1295 + Ipamorelin; anabolic GH/IGF stack

GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog

This Hulk Stack entry draws on 4 cited sources published 1996 to 2006. The evidence available is graded Anecdotal on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog
Drug class
Growth Hormone Secretion
Structure
Three-vial protocol rather than a single co-formulated vial: CJC-1295 (29-aa GHRH analog), Ipamorelin (pentapeptide), IGF-1 LR3 (70-aa engineered IGF-1 with Arg3 substitution and N-terminal extension)
Route
SC injection (typically 2-3 separate sites)
Half-life
CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs
Evidence tier
Anecdotal
Availability
Compounding Restricted

Mechanism of action

Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation.

Reported areas of research

Muscle accrual and recovery support through layered GH + IGF action; reported effects include improved recovery and lean-mass gain during dosing cycles

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved

Compared with

Hulk Stack has published head-to-head comparisons with 14 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for Hulk Stack in research literature?

Published peptide research reports the following dosing approach for Hulk Stack: Reported research dosing: CJC-1295 100-200 mcg with Ipamorelin 100-200 mcg SC nightly; IGF-1 LR3 20-50 mcg SC. Reported cycles run 4-8 weeks followed by ~4 weeks off; longer cycles increase desensitisation and IGF-1R-mediated risks. This is a research reference, not a clinical recommendation.

How is Hulk Stack administered in research?

Hulk Stack is administered via the following routes in published studies: SC injection (typically 2-3 separate sites).

What is the reported half-life of Hulk Stack?

The reported half-life of Hulk Stack is CJC no-DAC ~30 min; Ipamorelin ~2 hrs; IGF-1 LR3 ~20-30 hrs.

Is Hulk Stack FDA-approved?

No. Hulk Stack is not an FDA-approved drug. PeptideHelper.org catalog status: Compounding Restricted.

What level of evidence supports Hulk Stack?

The current evidence base for Hulk Stack is best characterised as: Anecdotal. See the methodology page for the full evidence-tier rubric.

What side effects are reported for Hulk Stack?

Known concerns reported in the literature for Hulk Stack include: Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved. Always consult a qualified clinician before any human use.

Is there anyone who should not use Hulk Stack?

No formal contraindications are established for Hulk Stack, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Compounds the risk profile of three potent compounds: hypoglycaemia (IGF-1), receptor desensitisation (GHRH + GHRP), theoretical organomegaly with chronic IGF-1 LR3 use, IGF-1R-mediated growth signal on any pre-existing tumour, WADA-banned across competitive sport, injection-site reactions; not FDA-approved. Always consult a qualified clinician before any human use.

How does Hulk Stack work?

The mechanism of action reported for Hulk Stack in the literature: Stacks pituitary GH release with downstream anabolic IGF-1 substrate. CJC-1295 (no-DAC) drives a pituitary GHRH-R pulse; Ipamorelin co-activates the ghrelin receptor without cortisol/prolactin spillover; IGF-1 LR3 supplies a 70-aa long-acting IGF-1 analog that bypasses IGFBP sequestration and directly engages the IGF-1R for sustained anabolic signalling. The GH/IGF axis is hit from both ends, endogenous pulse plus exogenous receptor activation..

What is Hulk Stack studied for?

Hulk Stack has been studied in the published literature for: Muscle accrual and recovery support through layered GH + IGF action; reported effects include improved recovery and lean-mass gain during dosing cycles. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is Hulk Stack?

Hulk Stack is classified as: GH + IGF stack: GHRH analog + selective GHRP + long-acting IGF-1 analog. Also known as: Hulk blend; IGF-1 LR3 + CJC-1295 + Ipamorelin; anabolic GH/IGF stack.

Drug class

Research focus area

All peptides studied for Growth Hormone Secretion, ranked by evidence tier and regulatory status.

Primary sources

  1. Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab 2006. PMID 16352683
  2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
  3. Tomas FM et al. Long-Arg3-IGF-I (LR3-IGF-I) restores muscle growth in rats. J Endocrinol 1996. PMID 8943755
  4. Note: The Hulk Stack is a community / vendor-marketed three-compound protocol with no published trial of the combination. Evidence is anecdotal; cited papers describe each component separately.

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…